Ramipryl: mechanizm działania, wskazania i działania niepożądane. Przegląd najważniejszych badań klinicznych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2009
Słowa kluczowe:
ramipryl, przerost lewej komory, niewydolność serca, choroba niedokrwienna serca, udar mózgu, nefropatia, cukrzyca
##plugins.themes.bootstrap3.article.main##
Abstrakt
Począwszy od badania HOPE, coraz więcej uwagi poświęca się zastosowaniu inhibitorów konwertazy angiotensyny (ACEI) u chorych podwyższonego ryzyka sercowo-naczyniowego. Poniższa praca prezentuje zastosowanie ramiprylu w schorzeniach układu krążenia oraz powikłaniach cukrzycy, w oparciu o mechanizmy działania ACEI oraz wyniki badań klinicznych.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dobosiewicz , A., Abramczyk , P., & Bidiuk , J. (2009). Ramipryl: mechanizm działania, wskazania i działania niepożądane. Przegląd najważniejszych badań klinicznych . Kardiologia W Praktyce, 3(2), 62-69. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1660
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Benzing T., Fleming I., Blaukat A. et al.: Angiotensin-converting-enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within plasma membrane of native endothelial cells. Circulation 1999, 99: 2034-2040.
2. Kasprzak J., Wejner-Mik P.: Zastosowanie inhibitorów konwertazy angiotensyny w chorobie niedokrwiennej serca. Kardiologia po Dyplomie. Wydanie specjalne. 2003.
3. Tummala P.E., Chen X.L., Sundell C.L. et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100: 1223-1229.
4. Warnholtz A., Nickenig G., Schulz E. et al.: Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin – angiotensin system. Circulation 1999, 99: 2027-2033.
5. Diet F., Pratt R.E., Berry G.J. et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94: 2756-2767.
6. Griendling K.K., Minieri C.A., Ollarenshaw J.D. et al.: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74: 1141-1148.
7. Kissner R., Nauser T., Bugnon P. et al.: Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem. Res. Toxicol. 1997, 10: 1285-1292.
8. Leeuwenburgh C., Hardy M.M., Hazen S.L. at al.: Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 1997, 272: 1433-1436.
9. Rao G.N., Berk B.C.: Active oxygen species stimulate vascular smooth muscle cell growth and protooncogene expression. Circ. Res. 1992, 70: 593-599.
10. Kahler J., Mendel S., Weckmuller J. at al.: Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J. Mol. Cell. Cardiol. 2000, 32: 1429-1437.
11.Todd P.A., Benfield P.: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990, 1: 110-135.
12. Drzewoski J.: Farmakokinetyka inhibitorów konwertazy angiotensyny. W: Leki hamujące enzym przekształcający angiotensynę, działanie i zastosowanie kliniczne. Adamska-Dyniewska H. (red.). Towarzystwo terapii monitorowanej, Łódź 1996: 62-76.
13. Frampton J.E., Peters D.H.: Ramipril an updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995 Mar, 49(3): 440-66.
14. Schmieder R.E, Martus P, Klingbeil A.: Reversal of left ventricular hypertrophy in essential hypertension: a metaanalysis of randomised double-blind studies. JAMA 1996, 275: 1507-1513.
15. Mathew J., Sleight P., Lonn E. et al.: Reduction of cardiovascular risk by regression of electocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, ramipril. Circulation 2001, 104: 1615-1621.
16. Lip G.: Regression of left ventricular hypertrophy and improved prognosis: some hope now…or hype. Circulation 2001, 104: 1582-1584.
17. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators (no authors listed). Lancet 1993, 342: 821-828.
18. Hall A.S., Murray G.D., Ball S.G. (on behalf of the AIREX study investigators): Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997 May 24, 349(9064): 1493-1497.
19. Fabre J.E., Rivard A., Magner M. et al.: Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999, 99: 3043-3049.
20. Halkin J.H., Keren G.: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am. J. Med. 2002, 112: 126-134.
21. Lonn E., Yusuf S., Dzavik V. et al.: Effects of Ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001, 103: 919-925.
22. Ambrose J., Martinez E.: A new paradigm for plaque stabilisation. Circulation 2002, 105: 2000-2004.
23. Dagenais G.R., Yusuf S., Bourassa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., Grover J. (HOPE Investigators): Effect of ramipril on coronary events in high-risk persons: results of the HOPE study. Circulation 2001, 104: 522-526.
24. Larose E., Tardif J., Bourassa M.G.: Use of ACE Inhibitors for Secondary Prevention. Current Treatment Options in Cardiovascular Medicine 2003, 5: 51-61.
25. Kjoller-Hansen l., Steffensen R., Grande P.: The angiotensin-converting enzyme inhibition post revascularization study (APRES). J. Am. Coll. Cardiol. 2000, 35: 881-888.
26. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davies R., Ostergren J., Probstfield J.: Use of ramipril in preventing stroke: double blind randomised trial. British Medical Journal 2002, 324: 699-702.
27. The ACE inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann. Intern. Med. 2001, 134: 370-379.
28. O’Hare P., Bilous R., Mitchell T. et al. (on behalf of the Atlantis Study Group): Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000 Dec, 23(12): 1823-9.
29. Fogari R., Zoppi A., Corradi L. et al.: Long- term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J. Hum. Hypertens. 1999 Jan, 13(1): 47-53.
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355: 253-259.
31. Ruggenenti P., Perna A., Gherardi G., Zoccali C., Salvadori M., Scolari F., Schena F.P., Remuzzi G.: Renoprotective properties of ACE- inhibition in non- nephropathies with non-nephrotic proteinuria. The Lancet 1999, 354: 359-364.
32. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in protinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997, 349: 1857-1863.
33. Ruggenenti P., Perna A., Loriga G. et al. (for the REIN-2 Study Group): Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005, 365: 939-946.
34. The ONTARGET Investigators: Telmisartan, Ramipril or both in patients at high risk for vascular events. N. Engl. J. Med. 2008, 358: 1547-1559.
35. Yusuf S., Gerstein H., Hoogwerf B. et al.: Ramipril and the development of diabetes. JAMA 2001, 286: 1882-5.
36. Bosch J., Yusuf S., Gerstein H.C. (DREAM Trial Investigators): Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006, 355: 1551-62.
37. Monarch Pharmaceuticals. Altace® Capsules (ramipril) [online: www.monarchpharm.com (Accessed 2001 Nov 28).
2. Kasprzak J., Wejner-Mik P.: Zastosowanie inhibitorów konwertazy angiotensyny w chorobie niedokrwiennej serca. Kardiologia po Dyplomie. Wydanie specjalne. 2003.
3. Tummala P.E., Chen X.L., Sundell C.L. et al.: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100: 1223-1229.
4. Warnholtz A., Nickenig G., Schulz E. et al.: Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin – angiotensin system. Circulation 1999, 99: 2027-2033.
5. Diet F., Pratt R.E., Berry G.J. et al.: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94: 2756-2767.
6. Griendling K.K., Minieri C.A., Ollarenshaw J.D. et al.: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74: 1141-1148.
7. Kissner R., Nauser T., Bugnon P. et al.: Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem. Res. Toxicol. 1997, 10: 1285-1292.
8. Leeuwenburgh C., Hardy M.M., Hazen S.L. at al.: Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 1997, 272: 1433-1436.
9. Rao G.N., Berk B.C.: Active oxygen species stimulate vascular smooth muscle cell growth and protooncogene expression. Circ. Res. 1992, 70: 593-599.
10. Kahler J., Mendel S., Weckmuller J. at al.: Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J. Mol. Cell. Cardiol. 2000, 32: 1429-1437.
11.Todd P.A., Benfield P.: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990, 1: 110-135.
12. Drzewoski J.: Farmakokinetyka inhibitorów konwertazy angiotensyny. W: Leki hamujące enzym przekształcający angiotensynę, działanie i zastosowanie kliniczne. Adamska-Dyniewska H. (red.). Towarzystwo terapii monitorowanej, Łódź 1996: 62-76.
13. Frampton J.E., Peters D.H.: Ramipril an updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995 Mar, 49(3): 440-66.
14. Schmieder R.E, Martus P, Klingbeil A.: Reversal of left ventricular hypertrophy in essential hypertension: a metaanalysis of randomised double-blind studies. JAMA 1996, 275: 1507-1513.
15. Mathew J., Sleight P., Lonn E. et al.: Reduction of cardiovascular risk by regression of electocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, ramipril. Circulation 2001, 104: 1615-1621.
16. Lip G.: Regression of left ventricular hypertrophy and improved prognosis: some hope now…or hype. Circulation 2001, 104: 1582-1584.
17. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators (no authors listed). Lancet 1993, 342: 821-828.
18. Hall A.S., Murray G.D., Ball S.G. (on behalf of the AIREX study investigators): Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997 May 24, 349(9064): 1493-1497.
19. Fabre J.E., Rivard A., Magner M. et al.: Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999, 99: 3043-3049.
20. Halkin J.H., Keren G.: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am. J. Med. 2002, 112: 126-134.
21. Lonn E., Yusuf S., Dzavik V. et al.: Effects of Ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001, 103: 919-925.
22. Ambrose J., Martinez E.: A new paradigm for plaque stabilisation. Circulation 2002, 105: 2000-2004.
23. Dagenais G.R., Yusuf S., Bourassa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., Grover J. (HOPE Investigators): Effect of ramipril on coronary events in high-risk persons: results of the HOPE study. Circulation 2001, 104: 522-526.
24. Larose E., Tardif J., Bourassa M.G.: Use of ACE Inhibitors for Secondary Prevention. Current Treatment Options in Cardiovascular Medicine 2003, 5: 51-61.
25. Kjoller-Hansen l., Steffensen R., Grande P.: The angiotensin-converting enzyme inhibition post revascularization study (APRES). J. Am. Coll. Cardiol. 2000, 35: 881-888.
26. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davies R., Ostergren J., Probstfield J.: Use of ramipril in preventing stroke: double blind randomised trial. British Medical Journal 2002, 324: 699-702.
27. The ACE inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann. Intern. Med. 2001, 134: 370-379.
28. O’Hare P., Bilous R., Mitchell T. et al. (on behalf of the Atlantis Study Group): Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000 Dec, 23(12): 1823-9.
29. Fogari R., Zoppi A., Corradi L. et al.: Long- term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J. Hum. Hypertens. 1999 Jan, 13(1): 47-53.
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355: 253-259.
31. Ruggenenti P., Perna A., Gherardi G., Zoccali C., Salvadori M., Scolari F., Schena F.P., Remuzzi G.: Renoprotective properties of ACE- inhibition in non- nephropathies with non-nephrotic proteinuria. The Lancet 1999, 354: 359-364.
32. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in protinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997, 349: 1857-1863.
33. Ruggenenti P., Perna A., Loriga G. et al. (for the REIN-2 Study Group): Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005, 365: 939-946.
34. The ONTARGET Investigators: Telmisartan, Ramipril or both in patients at high risk for vascular events. N. Engl. J. Med. 2008, 358: 1547-1559.
35. Yusuf S., Gerstein H., Hoogwerf B. et al.: Ramipril and the development of diabetes. JAMA 2001, 286: 1882-5.
36. Bosch J., Yusuf S., Gerstein H.C. (DREAM Trial Investigators): Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006, 355: 1551-62.
37. Monarch Pharmaceuticals. Altace® Capsules (ramipril) [online: www.monarchpharm.com (Accessed 2001 Nov 28).